The FDA has missed the deadline for making a key decision regarding a Novavax (NVAX.US) Covid-19 vaccine, days after the Food and Drug Administration’s vaccine chief was pushed out. Novavax’s application needed more data and was unlikely to be approved soon - was said by people familiar with a matter, citted by WSJ.
This information is seriously damaging the sentiment around the company and is undermining its current ability to maintain its business system. The shares are losing over 1.5%, although at one point the declines were as high as 4%.
Source: xStation
AI Stocks Slide 🚩 Dell Drops 11%
US Open: S&P 500 Gains on Softer PPI Inflation 🔼 Memory Stocks Slip, PayPal Surges 15%
Market Wrap: Indices gain on technology stocks rise and lower US PPI data
Micron vs. Nvidia: Wall Street's New AI Darling Has Soared 18-Fold Since ChatGPT